Melanotan II
Cyclic synthetic alpha-MSH analogue and melanocortin receptor agonist
Melanocortin-agonist research focused on pigmentation, with additional effects on sexual function observed.
Route
Subcutaneous research use.
Common format
10 mg vial
Research focus
melanogenesis
Evidence level
Limited Human Evidence
Typical cycle
6–8 weeks (loading)
SexualMelanotan II in 30 seconds
Atlas Fast ReadWhat it is
Cyclic synthetic alpha-MSH analogue and melanocortin receptor agonist
Why people care
Melanocortin-agonist research focused on pigmentation, with additional effects on sexual function observed.
Human evidence
Limited Human Evidence — Human interventional or clinical data exist, but studies are small, early-phase, mixed, indirect, route-specific, or not confirmatory.
Biggest misconception
Key gaps include larger independent trials, clearer dose-response data, long-term safety, clinically meaningful endpoints, and evidence that findings generalize beyond the narrow populations or routes already studied.
Bottom line
Melanotan II has a real human signal or documented human pharmacology, but evidence is too small, mixed, route-specific, or indication-specific to justify broad claims.
Overview
What is Melanotan II?
Melanotan II is cyclic synthetic alpha-MSH analogue and melanocortin receptor agonist. Melanocortin-agonist research focused on pigmentation, with additional effects on sexual function observed.
Melanotan analogues were developed from alpha-MSH research at the University of Arizona in the 1980s–1990s. Melanotan II was investigated for pigmentation and sexual effects but was never approved as a tanning drug.
Mechanism
How it works
Activates multiple melanocortin receptors, especially MC1R for melanogenesis and central MC3R/MC4R pathways that influence appetite and sexual arousal. Its broad receptor activity explains both desired and adverse effects.
Research areas
Evidence
What does the evidence actually say?
Human interventional or clinical data exist, but studies are small, early-phase, mixed, indirect, route-specific, or not confirmatory.
Preclinical Evidence
Limited Human Evidence
Strong Human Evidence
Human evidence
Preclinical evidence
Knowledge gaps
Protocol
Research protocol
Dose
Frequency
Timing
Route
Cycle length
Reconstitution
Storage
Monitoring
Protocols vary widely between sources. Investigational compounds are not approved therapies, and approved products should follow their official labeling. Nothing here is medical advice.
Safety
Safety, side effects, and precautions
Side effects
Contraindications
Interactions
Stacks
Common stacks
No well-supported stack is highlighted for this peptide yet.
Questions
FAQ
References
Sources
Atlas
The Atlas verdict
Melanotan II has a real human signal or documented human pharmacology, but evidence is too small, mixed, route-specific, or indication-specific to justify broad claims. The most defensible use of the literature is to separate what has actually been measured in people from what is still extrapolated from mechanism or animal work.